CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 168 filers reported holding CLOVIS ONCOLOGY INC in Q2 2021. The put-call ratio across all filers is 1.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $318,000 | -25.2% | 157,529 | +0.4% | 0.00% | – |
Q4 2021 | $425,000 | -33.1% | 156,902 | +10.2% | 0.00% | -100.0% |
Q3 2021 | $635,000 | -20.3% | 142,349 | +3.7% | 0.00% | 0.0% |
Q2 2021 | $797,000 | -9.2% | 137,333 | +9.8% | 0.00% | 0.0% |
Q1 2021 | $878,000 | +45.8% | 125,053 | -0.4% | 0.00% | 0.0% |
Q4 2020 | $602,000 | -17.8% | 125,505 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $732,000 | -0.5% | 125,505 | +15.1% | 0.00% | 0.0% |
Q2 2020 | $736,000 | +52.1% | 109,015 | +43.4% | 0.00% | 0.0% |
Q1 2020 | $484,000 | -40.8% | 76,042 | -3.1% | 0.00% | 0.0% |
Q4 2019 | $818,000 | +165.6% | 78,454 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $308,000 | -72.5% | 78,454 | +4.4% | 0.00% | -50.0% |
Q2 2019 | $1,118,000 | -38.2% | 75,175 | +3.1% | 0.00% | -50.0% |
Q1 2019 | $1,809,000 | +35.2% | 72,901 | -2.2% | 0.00% | +33.3% |
Q4 2018 | $1,338,000 | -37.4% | 74,522 | +2.3% | 0.00% | -25.0% |
Q3 2018 | $2,139,000 | -35.4% | 72,843 | -0.0% | 0.00% | -42.9% |
Q2 2018 | $3,313,000 | -6.3% | 72,868 | +8.9% | 0.01% | -12.5% |
Q1 2018 | $3,534,000 | -25.0% | 66,924 | -3.4% | 0.01% | -20.0% |
Q4 2017 | $4,710,000 | -18.8% | 69,270 | -1.5% | 0.01% | -23.1% |
Q3 2017 | $5,797,000 | -19.3% | 70,356 | -8.3% | 0.01% | -13.3% |
Q2 2017 | $7,185,000 | +56.2% | 76,735 | +6.2% | 0.02% | +66.7% |
Q1 2017 | $4,600,000 | +58.0% | 72,245 | +10.2% | 0.01% | +50.0% |
Q4 2016 | $2,912,000 | +19.9% | 65,545 | -2.7% | 0.01% | +20.0% |
Q3 2016 | $2,428,000 | +165.6% | 67,345 | +1.1% | 0.01% | +150.0% |
Q2 2016 | $914,000 | -19.3% | 66,645 | +13.1% | 0.00% | 0.0% |
Q1 2016 | $1,132,000 | -37.3% | 58,943 | +14.2% | 0.00% | -50.0% |
Q4 2015 | $1,806,000 | -61.3% | 51,609 | +1.8% | 0.00% | -66.7% |
Q3 2015 | $4,664,000 | -29.5% | 50,720 | -32.6% | 0.01% | -25.0% |
Q2 2015 | $6,614,000 | +97.3% | 75,264 | +66.7% | 0.02% | +100.0% |
Q1 2015 | $3,352,000 | +30.3% | 45,151 | -1.7% | 0.01% | +33.3% |
Q4 2014 | $2,573,000 | +24.5% | 45,951 | +0.9% | 0.01% | +20.0% |
Q3 2014 | $2,066,000 | +10.7% | 45,556 | +1.0% | 0.01% | 0.0% |
Q2 2014 | $1,867,000 | -17.3% | 45,097 | +38.3% | 0.01% | -16.7% |
Q1 2014 | $2,258,000 | +15.3% | 32,597 | +0.3% | 0.01% | +20.0% |
Q4 2013 | $1,959,000 | +12.3% | 32,497 | +13.2% | 0.01% | 0.0% |
Q3 2013 | $1,744,000 | +7.5% | 28,697 | +18.5% | 0.01% | 0.0% |
Q2 2013 | $1,622,000 | +138.2% | 24,222 | +2.0% | 0.01% | +150.0% |
Q1 2013 | $681,000 | – | 23,750 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |